scorecardresearch
Add as a preferred source on Google
Monday, April 20, 2026
TopicEli Lilly

Topic: Eli Lilly

In battle for Indian anti-obesity market, Eli Lilly’s pre-filled pen on one side, Novo Nordisk’s on other

India's anti-obesity drug market is currently valued at Rs 3,000-3,500 crore & is projected to grow nearly eightfold by 2030, according to market estimates.

Eli Lilly announces trial results for world’s 2nd weekly insulin, aims for launch by year-end

New Delhi: There is excitement and hope in the insulin market the world over after U.S. based pharma giant Eli Lilly & Company on...

Fat-busting drug Mounjaro launched in India. Here’s how much it will cost

US pharma giant Eli Lilly's Mounjaro can prove crucial in treatment of obesity & type 2 diabetes. Launched in the US in 2022, it has since become a global blockbuster.

Ozempic on steroids? Successor that could cut down weight in half the time coming soon

While Novo Nordisk says CagriSema will help users lose up to 25% of weight, duration will be clear when final results of its effectiveness in obesity management come out in 3 months.

Blockbuster diabetes & obesity drug gets nod for India launch but may be available only next year

Tirzepatide is a type 2 diabetes and obesity drug sold by US firm Eli Lilly under the brand names Mounjaro and Zepbound. It may take around 6 months for it to be launched in India.

Novartis, Eli Lilly oppose compulsory licences for breast cancer drugs, say sales up despite price

Pharma giants were responding to petition in Kerala HC seeking compulsory licences for their HER2-negative breast cancer drugs, which would allow cheaper, generic versions to be made.

Has a ‘magical’ weight loss drug finally arrived? Hopes soar with US firm’s never-before-seen results

Patients who got a weekly injection of the experimental anti-obesity drug retatrutide lost up to 24 per cent of their body weight in 48 weeks, show phase-2 trials published this week.

WHO approves Glaxo and Eli Lilly drugs to treat Covid amid Omicron surge

Eli Lilly’s rheumatoid arthritis drug and GlaxoSmithKline's monoclonal antibody won the WHO nod.

Blocked by Eli Lilly, Bajaj Healthcare moves patent office to make Covid drug Baricitinib

BHL says it can produce Baricitinib for as cheap as Rs 14 (for 1mg). US pharma giant Eli Lilly, which holds exclusive licence for the drug, manufactures it at an average cost of Rs 3,230.

On Camera

India’s close encounters with Pakistan on Siachen

Pakistan's SSG team was not adequately provisioned for the inclement weather. If it managed to consolidate its position, the story of Siachen would have been different. 

The rebirth of YES BANK, a financial thriller: How captains of industry brought it back from the brink

In March 2020, Prashant Kumar took over as CEO & MD overseeing YES Bank reconstruction. He was ably supported by veteran banker Sunil Mehta, CA Atul Bheda & consultant Mahesh Krishnamurti.

Why Siliguri Corridor is strategically important for India & how it is being secured | Cut The Clutter

This special edition of Cut The Clutter, straight from the Siliguri corridor, details the strategic importance of the narrow strip of land in West Bengal, and how it’s a vital link connecting the Northeast to the rest of India.

Trump, Netanyahu’s Iran gamble: The regime change rebound

American objectives are unmet. They neither have muscle nor motivation to resume the war. As for Iran, the regime didn’t just survive, it’s now led by more radical individuals.